<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(12)</volume><submitter>Ruiz-Saez H</submitter><pubmed_abstract>&lt;b>Background:&lt;/b> Headache is a common symptom during acute viral infections, and its pathophysiology has been linked with the immune response to the virus. Headache is one of the most frequent symptoms of coronavirus disease 2019 (COVID-19), and it has been associated with a more efficient immune response and a better prognosis. The aim of this article is to evaluate whether vaccination could modify the clinical phenotype and the probability of developing persistent headache after acute COVID-19. &lt;b>Methods:&lt;/b> A case-control study comparing the duration of the headache and the clinical phenotype between fully vaccinated individuals and non-vaccinated controls was conducted. Each case was matched with two controls that were paired by age, sex, and prior history of headache. Patients wer</pubmed_abstract><journal>Biomedicines</journal><pagination>2900</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12731189</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>COVID-19 Vaccination Modifies COVID-19-Related Headache Phenotype: Evidence from Case-Control Study on 309 Participants.</pubmed_title><pmcid>PMC12731189</pmcid><pubmed_authors>Blanco M</pubmed_authors><pubmed_authors>Martinez Badillo C</pubmed_authors><pubmed_authors>Recio-Garcia A</pubmed_authors><pubmed_authors>Hurtado ML</pubmed_authors><pubmed_authors>Sierra-Mencia A</pubmed_authors><pubmed_authors>Planchuelo-Gomez A</pubmed_authors><pubmed_authors>Nunez G</pubmed_authors><pubmed_authors>Echavarria Iniguez A</pubmed_authors><pubmed_authors>Cornejo A</pubmed_authors><pubmed_authors>Ruiz M</pubmed_authors><pubmed_authors>Garcia-Azorin D</pubmed_authors><pubmed_authors>Paniagua M</pubmed_authors><pubmed_authors>Gil A</pubmed_authors><pubmed_authors>Rojas-Hernandez M</pubmed_authors><pubmed_authors>Cubero M</pubmed_authors><pubmed_authors>Alberdi-Iglesias A</pubmed_authors><pubmed_authors>Gonzalez-Celestino A</pubmed_authors><pubmed_authors>Perez Almendro C</pubmed_authors><pubmed_authors>Mora M</pubmed_authors><pubmed_authors>Lozano AG</pubmed_authors><pubmed_authors>Fernandez-de-Las-Penas C</pubmed_authors><pubmed_authors>Montilla C</pubmed_authors><pubmed_authors>Ruiz-Saez H</pubmed_authors><pubmed_authors>Garcia-Iglesias C</pubmed_authors><pubmed_authors>Gonzalez Osorio Y</pubmed_authors><pubmed_authors>Calcerrada I</pubmed_authors><pubmed_authors>Guerrero Peral AL</pubmed_authors><pubmed_authors>Sierra L</pubmed_authors><pubmed_authors>Trigo Lopez J</pubmed_authors></additional><is_claimable>false</is_claimable><name>COVID-19 Vaccination Modifies COVID-19-Related Headache Phenotype: Evidence from Case-Control Study on 309 Participants.</name><description>&lt;b>Background:&lt;/b> Headache is a common symptom during acute viral infections, and its pathophysiology has been linked with the immune response to the virus. Headache is one of the most frequent symptoms of coronavirus disease 2019 (COVID-19), and it has been associated with a more efficient immune response and a better prognosis. The aim of this article is to evaluate whether vaccination could modify the clinical phenotype and the probability of developing persistent headache after acute COVID-19. &lt;b>Methods:&lt;/b> A case-control study comparing the duration of the headache and the clinical phenotype between fully vaccinated individuals and non-vaccinated controls was conducted. Each case was matched with two controls that were paired by age, sex, and prior history of headache. Patients wer</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-05-28T03:15:16.428Z</modification><creation>2026-05-28T03:08:02.643Z</creation></dates><accession>S-EPMC12731189</accession><cross_references><pubmed>41462912</pubmed><doi>10.3390/biomedicines13122900</doi></cross_references></HashMap>